bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of Product Development to accelerate the development of new diagnostics based on the proprietary technology platform behind CyPath® Lung, the Company’s commercial test for the detection of early-stage lung cancer.

Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, will hold a live conference call and webcast at 3:00 p.m. Central Time on Thursday, May 16, 2024, to discuss the company's first quarter financial results. The call will be hosted by Jay D. Miller, Chief Executive Officer and President and Andrew D. C. LaFrence, Chief Financial Officer. To access the live audio conference call, US participants may call 888-506-0062 and international participants may call 973-528-0011. Participant Access Code: 945063. Participants may ...

STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection (CDI) will be presented at the 34th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) being held in Barcelona, Spain, April 27-30, 2024.

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small cell lung cancer in never smokers and how drug candidate LP-300 and the Harmonic Clinical Trial is looking to change these outcomes.